A+
|
A
|
A-
|
Skip to main content
|
IPO
LOGIN
OPEN A DEMAT ACCOUNT
IPO
Login
Open a
Demat
Account
HOME
ABOUT US
PRODUCTS
Equity
Currency
Commodity
IPO
Mutual Funds
PMS
SLBM
SERVICES
Investment Banking
Institutional Equities
Wealth Management
Depository
TRADE WITH SYSTEMATIX
Partner With Us
Trading Simplified
Payment Gateway
Link UPI
KYC Updation
ReKYC
(Document Reactivation/Modification in Account/Nominee Registration/Account Closure)
Bank Details
Account Opening Process
Incapacitated investor
RESEARCH
MARKETS
Overview
Equity
IPO
Mutual Funds
Commodity
Company Info
INVESTORS
Investor Login
Investor Relations
Investor Grievances
ODR
Scores
Downloads
Investor Charter
Information to Physical Shareholders
Procedure for Filing a Complaint
Investor Education
CONTACT US
Our Reach
Careers
OPEN A DEMAT ACCOUNT
HOME
ABOUT US
PRODUCTS
EQUITY
CURRENCY
COMMODITY
IPO
MUTUAL FUND
PMS
SLBM
SERVICES
INVESTMENT BANKING
INSTITUTIONAL EQUITIES
WEALTH MANAGEMENT
DEPOSITORY
TRADE WITH SYSTEMATIX
PARTNER WITH US
TRADING SIMPLIFIED
PAYMENT GATEWAY
LINK UPI
KYC UPDATION
ReKYC (Document Reactivation/Modification in Account/Nominee Registration/Account Closure)
BANK DETAILS
ACCOUNT OPENING PROCESS
Incapacitated investor
RESEARCH
MARKETS
OVERVIEW
EQUITY
IPO
MUTUAL FUND
COMMODITY
COMPANY INFO
INVESTORS
INVESTOR LOGIN
INVESTOR RELATIONS
INVESTOR GRIEVANCES
ODR
SCORES
DOWNLOADS
INVESTOR CHARTER
INFORMATION TO PHYSICAL SHAREHOLDERS
PROCEDURE FOR FILING A COMPLAINT
Investor Education
CONTACT US
OUR REACH
CAREERS
Equity
Mutual Fund
IPO Analysis
Daily Market Tracker
Gainers & Losers
Value & Volume Toppers
52 Week Highs & Lows
New Highs & Lows
Buyers & Sellers
Out/Under Performers
Bulk Deals
Block Deals
Unusual Volume
Rising Volume
Exchange Holidays
5 Days Up & Down
Index Movers
Index Overview
Top Sectors
News & Analysis
Pre Session Commentary
Mid Session Commentary
End Session Commentary
Quick Review
Market Beat
Stock Alert
Hot Pursuit
Foreign Markets
Economy News
Corporate News
Corporate Results
Other Markets
Futures Markets
Corporate Information
Company Snapshot
Company Background
Board Of Directors
Balance Sheet
Profit & Loss
Quarterly Results
Key Financial Ratios
Share Holding Pattern
Previous Quarter Comp
Director's Report
Score Board
Mutual Fund Holdings
Announcements
Peer Comparison
Technical Chart
Corporate Actions
Announcements
Book Closure
Board Meetings
Bonus Issues
Rights Issues
Delisted Shares
Market Turnover
Name Change
Split Of Face Value
Event Calendar
Other Markets
ADR Prices
FII Investments
MF Investments
Forex Details
World Indices
GDR Prices
Equity
Commodity
Mutual Fund
IPO
Price Analysis
Volume Analysis
News Analysis
Market Option
Other Option
Company Information
Gainers & Losers
52 Week High Low
News Highs and Low
Advances & Declines
Home
Market Info
Corporate Information
Company Snapshot
Company Snapshot
BSE
Glenmark Pharmaceuticals Ltd
BSE Code
532296
ISIN Demat
INE935A01035
Book Value (₹)
848.31
Div & Yield %
0.12
Market Cap (
₹
Cr.)
59,737.68
P/E *
40.27
EPS *
52.57
Face Value (₹)
1
* Profit to Earning Ratio
* Earning Per Share
Stock Price Details
Last Price (₹)
2,144.85
Change
111.40 (5.26%)
Best Buy (₹)
0.00
Best Sell (₹)
0.00
Today's Range
2,138.00 - 2,240.00
52-Week Range
1,336.95 - 2,286.15
Beta (1 Year)
0.52
Chart
1 Day
|
5 Day
|
3 Month
|
1 Year
|
5 Year
Corporate Announcements
Glenmark receives USFDA approval for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg
Glenmark Pharma secures USFDA nod for Fluticasone Propionate Inhalation Aerosol
Glenmark Pharmaceuticals Inc. to launch Sodium Phosphates Injection USP
Glenmark Pharma’s USA arm to market Sodium Phosphate injection in April 2026
Glenmark Pharmaceuticals Ltd gains for third straight session
Glenmark Pharmaceuticals consolidated net profit rises 15.88% in the December 2025 quarter
Glenmark Pharmaceuticals to convene board meeting
Benchmarks trade sideways; metal shares shine
Glenmark USA launches Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial
Glenmark Pharma’s US arm launches Epinephrine Injection in American market
Corporate Details
Incorporation Year :
1977
Chairman :
Glenn Saldanha
Ownership Group :
Indian Private
Sector :
Pharmaceuticals
Industry :
Pharmaceuticals - Indian - Bulk Drugs & Formln
Registered Office :
Glenmark Pharmaceuticals Ltd
B/2 Mahalaxmi Chambers,
22 Bhulabhai Desai Road,
Mumbai,
Maharashtra - 400026,
Phone : 91-22-40189999,
Fax : 91-22-40189986
E-Mail :
complianceofficer@glenmarkpharma.com
URL :
http://www.glenmarkpharma.com
Investor Returns
Period
Date
Price
Returns (%)
1Week
04-Mar-2026
2,040.10
9.22
1Month
10-Feb-2026
1,956.30
13.90
3Month
10-Dec-2025
1,952.90
14.10
6Month
10-Sep-2025
2,131.35
4.55
1Year
10-Mar-2025
1,401.65
58.97
Mutual Funds Holding
Scheme Name
% Holding
Market Value
HDFC Mid Cap Fund
2.91
2738.25
Invesco India Midcap Fund
3.70
398.29
Invesco India Contra Fund
1.87
372.96
ICICI Pru Equity - Arbitrage..
0.98
324.03
SBI Arbitrage Opportunities ..
0.66
291.18
Peerset : Pharmaceuticals - Indian - Bulk Drugs & Formln
Company
Last Price (₹)
Change (%)
52Week High (₹)
52Week Low (₹)
Market Cap (₹ Cr.)
Sun Pharmaceutical Industries Ltd
1,813.00
0.30
1,850.95
1,547.25
434,999.43
Dr Reddys Laboratories Ltd
1,313.90
2.14
1,377.95
1,025.90
109,663.75
Cipla Ltd
1,333.10
0.60
1,672.20
1,283.00
107,685.24
Lupin Ltd
2,340.75
1.70
2,368.00
1,774.00
106,982.39
Zydus Lifesciences Ltd
922.90
1.57
1,059.00
797.05
92,865.33
Index Details
BSE 500, BSE HC, BSE Midcap, BSE Shariah 50